With programs specifically developed for Oracle’s regional customer communities, this multifaceted event provides compelling sessions led by Oracle customers and industry thought leaders.
Has the global pandemic disrupted our journey or cleared the path for us in advancing clinical research? Hear from Oracle Health Sciences SVP and General Manager, Henry McNamara, as he explores the answer to this question.
SVP and GM, Oracle Health Sciences
With the advent of mRNA & DNA vaccines for COVID-19, the field of gene-related therapies has been fast-tracked by a decade. Before the paradigm shifted from chemical drugs to gene therapies, “mRNA, PCR & genomic variants” had already started to become household names.
Although there are approximately 10,000 known drugs for the treatment of 500 medical conditions, over 6,000 conditions remain unmet, many of which can be attributed to dysfunctional genes that have the possibility of correction. With the establishment of CAR-T for cancer after its first approval by FDA in 2017, and over 3500 gene therapy clinical trials ongoing, what will the future of pharma look like? Will the COVID crisis galvanize and fast-forward some of these pathbreaking therapies? Join Dr. Dhananjay Bakhale, the Executive Vice President of Medical Research at Lupid Ltd., for a session that gazes into the bright future of pharma.
Executive Vice President Medical Research, Lupin Ltd
This session will review the differences between a unified platform and an integrated eClinical platform in detail and why a unified platform brings greater quality and innovation to both the front end and back end office.
Global Vice President, Life Sciences Product Strategy, Oracle Health Sciences
Enterprise Strategy Architect, Oracle Health Sciences
Vice President, Development, Oracle Health Sciences
Panel session discussing next generation clinical trial management needs, and how sponsors and CROs can collaborate on trial management and oversight within the same platform, eliminating data redundancy, integrations and status reporting needs.
VP, Global Clinical Monitoring, Central Monitoring Services, Syneos Health
CPM, MS, Senior Director, Clinical Systems & Records, Global Clinical Operations & Planning, Daiichi Sankyo, Inc.
Director, Life Sciences Product Strategy, Oracle Health Sciences
Decentralized trials are fast becoming the new norm. This session will explore decentralized trials and the impact on Patients, Sites and Sponsors, as well as examine how can we simplify adoption and maximize this new approach to accelerate research.
CEO, Avance Clinical
In this session, learn how to enhance compliance, fast-track innovation, and unlock the full potential of the Oracle Health Sciences cloud solutions by leveraging Techsol's integrated add-on technologies, and process & validation/ assurance accelerators.
Associate Director, Client Partner, SEA & ANZ, Techsol
Vice President, Global Service Operations, Techsol
Hear our latest strategy to evolve our suite of safety products (Argus, Empirica, and Safety One Intake) to modernize the industry-leading safety applications and bring them closer to Clinical One to form one source of truth across clinical and safety.
Vice President, Safety Product Strategy, Oracle Health Sciences
Our Regulations and Audits Working Group stays on top of all of the regulatory impacts facing our customers. In this session, we will present the latest updates covering global safety regulators.
Principal Product Manager, Oracle Health Sciences
Join us for a discussion with the leading drug safety industry experts about the challenges and future of pharmacovigilance operations and systems.
VP, Medical Affairs & Head Global PV, Sun Pharma
SGM Global Head – PV, Lupin Ltd
Director Global Patient Safety, Advanz Pharma
Senior Director, Solutions Consulting, Asia Pacific, Oracle Health Sciences
Explore Oracle Health Sciences solutions and resources.